-mab

Appendix:Variations of "mab" English Etymology From en MAb, en monoclonal antibody m(onoclonal) a(nti)b(ody) 1. Pronunciation en /mæb/ Suffix en pharmacology monoclonal antibody Usage notes USAN guidelines for non-proprietary names of monoclonal antibodies are as follows: an arbitrary prefix to create a unique name (officially monosyllabic) a suffix for the disease state a suffix for the animal source -mab to identify it as a monoclonal antibody (MAb) The source suffixes are as follows: -a- for rat-derived, -e- for hamster, -i- for primate, -o- for mouse, -u- for human, -xi- for chimeric, -zu- for humanized, -xizu- for humanized and chimeric, -axo- for rat–mouse hybrid. The disease target suffixes are: -vir- viral, -bac- bacterial, -lim- immune system, immunomodulator, -les- infectious lesions, -cir- cardiovascular -col- colon tumor, -mel- melanoma, -mar- mammary tumor, -got- testicular (gonad) tumor, -gov- ovarian (gonad) tumor, -pro- prostate tumor, -tum- other tumors, or combinations of the above; -ner- nervous system, -kin- interleukin, -mul- musculoskeletal, -os- bone, -toxa- toxin, -fung- fungus Other attested target affixes are -anibi- and -neur-. The target affix takes the primary stress. For instance, capromab is a murine MAb that targets prostate cancer; imiciromab pentatate is used to target myocardial infarctions; satumomab pendetide is used for both colorectal and ovarian cancers. For humanized (-zu-) and chimeric (-xi-) MAbs (and -xizu-), the final consonant of the target suffix is dropped, and for all others the o of -pro- and the a of -toxa- is dropped: natalizumab, a humanized monoclonal antibody used in the treatment of multiple sclerosis (an immunological disease). Derived terms en Related terms en -ab en -pab for polyclonal antibodies en -tinib for tyrosine kinase inhibitors References USP Dictionary of USAN and International Drug Names, U.S. Pharmacopeia, 2000 AMA (USAN) Monoclonal antibodies, USAN, 2007 Anagrams en abm amb. amb BMA Bam MBA bam ABM BAM B. M. A. Mba en Medicine